VST BIO is a preclinical-stage biotechnology company focused on vascular diseases, e.g., developing first-in-class antibodies targeting edema and inflammation for patients with ischemic stroke. The company's lead candidate, VB-001 has demonstrated efficacy in a number of diseases including stroke, sepsis, and has the potential to reduce cytokine release syndrome in a number of clinical settings.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/17/26	undisclosed	Series A	Coefficient Giving	undisclosed